Positive Phase 2 Results for LYR-210 in Chronic Rhinosinusitis (CRS)

AS MUCH AS 6 MONTHS OF BENEFIT AFTER A SINGLE TREATMENT*

RAPID THERAPEUTIC ONSET

70%
of patients showed
clinically meaningful
improvement by
week 4*

DURABLE THERAPEUTIC RESPONSE

100%
of patients showed
clinically meaningful
improvement by
week 24*

BROAD PATIENT APPLICABILITY

non-polypoid disease
polypoid disease

*Based on LANTERN Phase 2 data with 7500 mcg dose, measured with SNOT-22.

 

The 22-item Sino-Nasal Outcome Test (SNOT-22) is a validated clinical score ranging from 0 to 110 and includes 22 items assessing symptoms and symptom impact associated with CRS. The meaningful clinically important difference is -8.9.

SNOT: Hopkins C et al. Clin. Otolaryngol. 2009, 34, 447-454

LYR-210 is an investigational product candidate that is designed to enable six-months of local anti-inflammatory therapy from a single treatment for CRS. LYR-210 is designed as a non-invasive alternative to sinus surgery for the millions of CRS patients who have failed medical management.
Back to Top